Galena Biopharma (NASDAQ: GALE) and Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, risk, profitabiliy, analyst recommendations, valuation, earnings and dividends.

Analyst Recommendations

This is a summary of current ratings and target prices for Galena Biopharma and Adamis Pharmaceuticals Corporation, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Galena Biopharma 0 4 0 0 2.00
Adamis Pharmaceuticals Corporation 0 0 2 0 3.00

Galena Biopharma currently has a consensus target price of $2.78, suggesting a potential upside of 396.43%. Adamis Pharmaceuticals Corporation has a consensus target price of $7.50, suggesting a potential upside of 78.57%. Given Galena Biopharma’s higher possible upside, analysts plainly believe Galena Biopharma is more favorable than Adamis Pharmaceuticals Corporation.

Earnings and Valuation

This table compares Galena Biopharma and Adamis Pharmaceuticals Corporation’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Galena Biopharma N/A N/A -$27.83 million ($0.94) -0.60
Adamis Pharmaceuticals Corporation $9.51 million 12.17 -$21.54 million N/A N/A

Adamis Pharmaceuticals Corporation has higher revenue and earnings than Galena Biopharma.

Risk and Volatility

Galena Biopharma has a beta of 1.88, meaning that its share price is 88% more volatile than the S&P 500. Comparatively, Adamis Pharmaceuticals Corporation has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500.

Profitability

This table compares Galena Biopharma and Adamis Pharmaceuticals Corporation’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Galena Biopharma N/A -14.89% -5.27%
Adamis Pharmaceuticals Corporation -197.55% -87.56% -54.69%

Insider & Institutional Ownership

22.2% of Galena Biopharma shares are held by institutional investors. Comparatively, 11.3% of Adamis Pharmaceuticals Corporation shares are held by institutional investors. 0.8% of Galena Biopharma shares are held by insiders. Comparatively, 12.2% of Adamis Pharmaceuticals Corporation shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Galena Biopharma beats Adamis Pharmaceuticals Corporation on 6 of the 11 factors compared between the two stocks.

About Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302. The Company’s NeuVax is in Phase III breast cancer clinical trial with several concurrent Phase II trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase IIa clinical trial in ovarian and endometrial cancers and in a Phase Ib clinical trial given sequentially with GALE-302. The Company’s therapies utilize an immunodominant peptide combined with the immune adjuvant, recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF, Leukine), and work by harnessing the patient’s own immune system to seek out and attack any residual cancer cells.

About Adamis Pharmaceuticals Corporation

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology.

Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.